BOSTON, Massachusetts — January 6, 2026 — Leads & Copy — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) announced that CEO and Founder Jean-Pierre Sommadossi, PhD, will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026, at 7:30 a.m. PT in San Francisco, CA, along with other members of the Atea management team.
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing oral antiviral therapeutics for serious viral diseases.
A live webcast of the presentation will be available here and on the Company’s website at https://ir.ateapharma.com. An archived webcast will be available on Atea’s website for at least 90 days following the event.
Atea leverages its understanding of antiviral drug development, nucleos(t)ide chemistry, biology, biochemistry, and virology to build a proprietary nucleos(t)ide prodrug platform. This platform is used to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of serious viral diseases. Atea plans to continue building its pipeline of antiviral product candidates by augmenting its nucleos(t)ide platform with other classes of antivirals that may be used in combination with its nucleos(t)ide product candidates.
Atea’s lead program is the regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, to treat HCV.
Jonae Barnes
SVP, Investor Relations and Corporate Communications
617-818-2985
barnes.jonae@ateapharma.com
Joyce Allaire
LifeSci Advisors
Jallaire@lifesciadvisors.com
Source: Atea Pharmaceuticals
